Concepedia

Author

Charlotte Kopitz

Bayer (Germany)

Also Known As

C Kopitz, C. Kopitz, Charlotte C. Kopitz, Charlotte Christine Kopitz, Charlotte Kopitz

151

Publications

2.7K

Citations

21

H-Index

20

Concepts

All Affiliations

Bayer (Germany)Klinikum rechts der IsarTechnical University of MunichBroad InstituteRadboud Institute for Molecular Life Sciences
CK

About

Charlotte Kopitz is an author at Bayer (Germany) specializing in medicine, tumor microenvironment, and tumor biology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

8

8

889

2

Cell Biology

5

5

672

3

Immunology

3

3

217

4

Health Sciences

1

1

20

5

Hepatology

1

1

20

Charlotte Kopitz

×

25

Publications

2.6K

Citations

20

H-Index

YearCitations

Mitochondrial complex I inhibition triggers a mitophagy-dependent ROS increase leading to necroptosis and ferroptosis in melanoma cells

Farhan Basit, Lisanne MPE van Oppen, Laura Schöckel,

Cell Death and Disease

2017

551

Evidence for an alternative fatty acid desaturation pathway increasing cancer plasticity

Kim Vriens, Stefan Christen, Sweta Parik,

Nature

2019

468

Anetumab Ravtansine: A Novel Mesothelin-Targeting Antibody–Drug Conjugate Cures Tumors with Heterogeneous Target Expression Favored by Bystander Effect

Sven Golfier, Charlotte Kopitz, Antje Kahnert,

Molecular Cancer Therapeutics

2014

245

Targeting mitochondrial complex I using BAY 87-2243 reduces melanoma tumor growth

Laura Schöckel, Andrea Glasauer, Farhan Basit,

Cancer & Metabolism

2015

155

Tissue Inhibitor of Metalloproteinases-1 Promotes Liver Metastasis by Induction of Hepatocyte Growth Factor Signaling

Charlotte Kopitz, Michael Gerg, Obul Reddy Bandapalli,

Cancer Research

2007

141

Hydroxamate-type matrix metalloproteinase inhibitor batimastat promotes liver metastasis.

Achim Krüger, R Soeltl, Igor Sopov,

PubMed

2001

127

Antimetastatic Activity of a Novel Mechanism-Based Gelatinase Inhibitor

Achim Krüger, Matthias Arlt, Michael Gerg,

Cancer Research

2005

123

Preclinical Efficacy of the Novel Monocarboxylate Transporter 1 Inhibitor BAY-8002 and Associated Markers of Resistance

Maria Quanz, Eckhard Bender, Charlotte Kopitz,

Molecular Cancer Therapeutics

2018

106

Rogaratinib: A potent and selective pan‐FGFR inhibitor with broad antitumor activity in FGFR‐overexpressing preclinical cancer models

Sylvia Grünewald, Oliver Politz, Sebastian Bender,

International Journal of Cancer

2019

89

Preclinical Efficacy of the Auristatin-Based Antibody–Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors

Anette Sommer, Charlotte Kopitz, Christoph A. Schatz,

Cancer Research

2016

73

Page 1